Topiramate modulates excitability of the occipital cortex when measured by transcranial magnetic stimulation

Cephalalgia

Volumn 30, Issue 6, 2010, Pages 648-654

  Aurora, S K ^a   Barrodale, P M ^a   Vermaas, A R ^a   Rudra, C B ^a  

^a Swedish Headache Center   (United States)

Author keywords

Chronic migraine; Excitability; MSPA; Topiramate; Transcranial magnetic stimulation

Indexed keywords

TOPIRAMATE;

ADULT; ARTICLE; AUTOANALYSIS; AUTOMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; EXCITABILITY; FEMALE; HUMAN; MALE; MEASUREMENT; MIGRAINE; NEUROMODULATION; OCCIPITAL CORTEX; STATISTICAL SIGNIFICANCE; TRANSCRANIAL MAGNETIC STIMULATION; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL STIMULATION;

FRUCTOSE; HUMANS; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL CORTEX; VISUAL PERCEPTION;

EID: 77956238965     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2009.01998.x     Document Type: Article

References (24)

1. Mathew NT, Stubits E, Nigam M. Transformation of migraine into daily headache: analysis of factors. Headache 1982;22:66-8.
2. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497-506.
3. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999;39:190-6.
4. Wang HZ, Simonson TM, Greco WR, Yuh W T C. Brain MR imaging in the evaluation of chronic headache in patients without other neurologic symptoms. Acad Radiol 2001;8:405-8.
5. Weingarten S, Kleinman M, Elperin L, Larson EB. The effectiveness of cerebral imaging in the diagnosis of chronic headache. Arch Intern Med 1992;152:2457-62.
6. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine: the population-based MRI CAMERA study. Brain 2005;128:2068-77.
7. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Brainstem and cerebellar hyperintense lesions in migraine. Stroke 2006;37:1109-12.
8. Aurora SK, Al-Sayed F, Welch K M A. The threshold for magnetophosphenes is lower in migraine. Cephalalgia 2003;23:258-63.
9. Young WB, Oshinsky ML, Shechter AL, Wassermann EM. Consecutive transcranial magnetic stimulation induced phosphene thresholds in migraineurs and controls. Neurology 2001;56: A142.
10. Fierro B, Ricci R, Piazza A, Scalia S, Giglia G, Vitello G, Brighina F. 1Hz rTMS enhances extrastriate cortex activity in migraine: evidence of a reduced inhibition? Neurology 2003;61:1446-8.
11. Mulleners WM, Chronicle EP, Palmer JE, Koehler PJ, Vredeveld JW. Suppression of perception in migraine: evidence for reduced inhibition in the visual cortex. Neurology 2001;56:178-83.
12. Moliadze V, Zhao Y, Eysel U, Funke K. Effect of transcranial magnetic stimulation on single-unit activity in the cat primary visual cortex. J Physiol 2003;553:665-79.
13. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache 2007;47:996-1003. (discussion 1004-7).
14. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62.
15. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73.
16. Diener HC, Tfelt-Hansen P, Dahlöf C, Láinez MJ, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50.
17. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5.
18. Silberstein SD. Topiramate in migraine prevention. Headache 2005;45(Suppl. 1):S57-65.
19. Mulleners WM, Chronicle EP, Vredeveld JW, Koehler PJ. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. Eur J Neurol 2002;9:35-40.
20. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004;24(Suppl. 1):1-160.
21. McGraw PV, Winn B. Glasgow Acuity Cards-a new test for the measurement of letter acuity in children. Ophthalmic Physiol Opt 1993;13:400-4.
22. Grimm W, Rassow B, Wesemann W, Saur K, Hilz R. Correlation of optotypes with the landolt ring-a fresh look at the comparability of optotypes. Optom Vis Sci 1994;71:6-13.
23. Reis J, Tergau F, Hame HM, Muller HH, Knake S, Fritsch B, et al. Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia 2002;43:1149-56.
24. Artemenko AR, Kurenkov AL, Filatova EG, Nikitin SS, Kaube H, Katsarava Z. Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine. Cephalalgia 2008;28:203-8.